Q-omics provides the consensus-scored SCAND2P profile across patient tissues and cancer cell-line models. SCAND2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SCAND2P is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SCAND2P RNA expression shows 21,446 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KIRC, and UVM as cancer lineages where SCAND2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCAND2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCAND2P survival associations across molecular data types. SCAND2P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCAND2P RNA expression–survival associations across cancer types. High SCAND2P expression shows unfavorable associations in COAD and ACC, but favorable associations in PAAD, BRCA, UCS and KIRC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for SCAND2P RNA expression.
This table summarizes SCAND2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCAND2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCAND2P shows lower tumor expression in THCA, KICH, BRCA and KIRP and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher SCAND2P RNA expression in tumor versus normal tissue (log2 FC = +0.410, t-test p < 0.001).
This table shows molecular features associated with SCAND2P in patient tissues and cancer cell lines. In patient samples, SCAND2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCAND2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and NCI60_ALL.
